课题基金 / 基金详情

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
肾脏 HEIR 研究:青年发病 2 型糖尿病研究中的肾脏血流动力学、能量学和胰岛素抵抗
批准号:
10397016
负责人:
Petter M Bjornstad
金额:
$19.22万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-01 至 2023-04-30
关键词:
AddressAdipose tissueAdolescentAdultAlbuminuriaAutomobile DrivingBeta CellBlood Plasma VolumeCardiologyChicagoChildhoodClinical InvestigatorClinical TrialsClosure by clampColoradoComplexConsumptionDataData AnalysesData CollectionDevelopmentDiabetic NephropathyDiseaseEndocrinologyEquationExperimental ModelsFunctional disorderGlomerular Filtration RateGlucoseGlucose ClampGoalsGoldHealthHigh PrevalenceHyperglycemiaHypergravityHypertensionInsulin ResistanceInterventionIntervention StudiesIohexolKidneyKidney DiseasesKidney FailureLearningMagnetic Resonance ImagingMeasuresMentored Patient-Oriented Research Career Development AwardMentorsMetabolicMethodologyMethodsNephrologyNon-Insulin-Dependent Diabetes MellitusNonesterified Fatty AcidsObesityObesity EpidemicOxygenPathologyPathway interactionsPatientsPerformancePerfusionPeripheralPersonsPhenotypePrevalenceRadiology SpecialtyRenal Plasma FlowResearchResearch DesignResearch MethodologyResearch PersonnelResistanceRiskTechniquesTestingThinnessTimeTissuesTrainingTranslational ResearchUnited StatesUniversitiesYouthanimal dataarterial spin labelingblood oxygen level dependentcareerexperiencefatty acid oxidationhemodynamicsimprovedinsulin sensitivitylifetime riskmid-career facultymortalitymultidisciplinarynew therapeutic targetnon-diabeticnovel therapeutic interventionnovel therapeuticsoxidationpatient oriented researchpre-clinicalpressurepublic health prioritiesrenal damagerenal hypoxiastandard measurestemtherapeutically effectivetranslational study

项目摘要

项目成果

Petter M Bjornstad的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Diabetic kidney disease (DKD) is the leading cause of renal failure in the United States. Current treatments, such as control of hyperglycemia and hypertension, are beneficial, but only partially protective in patients with type 2 diabetes (T2D). Clinical trials in DKD have yielded disappointing results, partly due to limited understanding of what initiates DKD, a potentially misguided focus on albuminuria, and lack of intervention at an early stage of disease when benefit is most likely. Therefore, identifying new therapeutic targets to impede progression of DKD remains a public health priority. Early DKD, including hyperfiltration, is common in youth with T2D. Renal hypoxia, stemming from a mismatch between renal oxygen utilization and consumption, is increasingly proposed to be a unifying pathway in the development of DKD. The kidneys have a high-energy requirement to sustain normal hemodynamic function. However, in T2D, there are emerging animal data that the kidneys are not able to sufficiently compensate for hyperfiltration and the effects of insulin resistance (IR) on fuel utilization. The pathophysiology underlying the relationship between IR and early DKD in youth-onset T2D is unclear, and it remains unproven whether the relationship is attributed to changes in intrarenal hemodynamic function and/or renal hypoxia. Dedicated translational studies are needed to unravel the complex metabolic pathophysiology behind the development of DKD in T2D. Dr. Bjornstad is establishing himself as a young investigator who is committed to patient-oriented research focused on early DKD. This K23 award would provide Dr. Bjornstad with the support necessary to accomplish the following goals: 1) to define intrarenal hemodynamic function (by iohexol and para-aminohippurate clearance); 2) renal oxygenation and perfusion (by MRI) in T2D youth vs. obese and lean controls, and between T2D youth with and without hyperfiltration; 3) to test the associations between insulin sensitivity (by hyperinsulinemic-euglycemic clamp) with intrarenal hemodynamic function and renal oxygenation. This proposal will provide dedicated time for Dr. Bjornstad to 1) perform translational research in a multi- disciplinary setting that integrates expertise from the fields of endocrinology, nephrology, cardiology and radiology; 2) gain hands-on experience in patient-oriented research, including primary data collection and analysis, study design, and execution; 3) acquire expertise in advanced and unique translational research methods; 4) set the platform for a career as an independent clinical investigator focused on interventional studies that will test novel therapies to impede the development of early DKD. To achieve these goals, Dr. Bjornstad has assembled a nationally-recognized mentoring team led by his primary mentors, Dr. Nadeau, Associate Professor of Pediatric Endocrinology and Dr. Johnson, Chief of Division of Nephrology at University of Colorado, Denver (UCD), in addition a broader mentor team composed of Drs. Truong (Cardiology/Radiology, UCD), Prasad (Radiology, U. of Chicago) and Cherney (Nephrology, U. of Toronto).
期刊论文(55)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.xkme.2020.05.013
发表时间: 2020-09
期刊: Kidney medicine
影响因子: 3.9
作者: [Seegmiller JC, Wolfe BJ, Albtoush N, Melena I, Gross SP, Vinovskis C, Ix JH, Bjornstad P]
通讯作者: Bjornstad P
DOI: 10.1042/cs20210627
发表时间: 2022-11-11
期刊: Clinical science (London, England : 1979)
影响因子: --
作者: []
通讯作者:
Loss of Glomerular Permselectivity in Type 2 Diabetes Associates With Progression to Kidney Failure.
2 型糖尿病肾小球通透性丧失与肾衰竭进展相关。
DOI: 10.2337/db23-0310
发表时间: 2023
期刊: Diabetes
影响因子: 7.7
作者: [Saulnier,PierreJ, Looker,HelenC, Layton,Anita, Lemley,KevinV, Nelson,RobertG, Bjornstad,Petter]
通讯作者: Bjornstad,Petter
DOI: 10.1016/s2213-8587(22)00075-4
发表时间: 2022-05
期刊: The lancet. Diabetes & endocrinology
影响因子: --
作者: []
通讯作者:
26
    Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
    • 批准号:
      10672454
    • 项目类别:
    • 资助金额:
      $61.99万
    • 财政年份:
      2022
    • 负责人:
      Petter M Bjornstad
    • 依托单位:
    Pathogenesis of kidney disease in type 1 diabetes: a modern kidney biopsy cohort
    • 批准号:
      10627851
    • 项目类别:
    • 资助金额:
      $59.12万
    • 财政年份:
      2022
    • 负责人:
      Petter M Bjornstad
    • 依托单位:
    Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
    • 批准号:
      10507929
    • 项目类别:
    • 资助金额:
      $61.81万
    • 财政年份:
      2022
    • 负责人:
      Petter M Bjornstad
    • 依托单位:
    Pathogenesis of kidney disease in type 1 diabetes: a modern kidney biopsy cohort
    • 批准号:
      10420966
    • 项目类别:
    • 资助金额:
      $63.92万
    • 财政年份:
      2022
    • 负责人:
      Petter M Bjornstad
    • 依托单位:
    海外基金